AI tool identifies patients most likely to benefit from extended endocrine therapy in hormone receptor-positive breast cancer
Dr Laura van't Veer talks to ecancer at ESMO 2026 about the development and validation of an AI-based digital pathology assay designed to predict breast cancer recurrence risk using routine tissue samples.
The model was trained on 70,000 whole-slide images to reproduce the prognostic information provided by the 70-gene MammaPrint assay and validated in 372 patients from the RASTER study.
After a median follow-up of 10.3 years, the digital assay demonstrated strong concordance with MammaPrint (r=0.954) and successfully distinguished patients at high and low risk.
Ten-year breast cancer-specific survival was 98.1% in the low-risk group versus 86.7% in the high-risk group.
The digital assay also outperformed conventional clinical factors in predicting outcomes.
These findings suggest that AI-driven digital pathology could improve access to personalised recurrence risk assessment in early-stage breast cancer.
AI tool identifies patients most likely to benefit from extended endocrine therapy in hormone receptor-positive breast cancer
ASCO 2026: Comment: Multi-cancer earlier detection tests
SABCS 2025: Latest developments in multigene testing in early breast cancer
MRD validated as a surrogate endpoint for survival in AML
AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer
AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
Enhancing breast cancer care through AI and collaboration
Disparities in mammogram screening amongst LGBTQ+ populations
ctDNA evaluation may play a prognostic role in stage III colon cancer treated with celecoxib